Active Ingredient History
Vildagliptin, sold under the brand name Galvus and others, is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aged (Phase 4)
Anesthesia (Phase 2/Phase 3)
Bone Diseases, Metabolic (Phase 4)
Cognitive Dysfunction (Phase 4)
Coronary Artery Disease (Phase 4)
Depressive Disorder, Major (Phase 1/Phase 2)
Diabetes Mellitus, Type 1 (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diagnostic Self Evaluation (Phase 1)
Dyslipidemias (Phase 2)
Endothelial Cells (Phase 4)
Exercise (Phase 4)
Foot Ulcer (Phase 4)
Glucose Intolerance (Phase 2)
Healthy Volunteers (Phase 3)
Heart Failure (Phase 4)
Hypertension (Phase 4)
Hypoglycemia (Phase 4)
Hypoglycemic Agents (Phase 4)
Inflammation (Phase 4)
Insulin Resistance (Phase 3)
Kidney Failure, Chronic (Phase 1/Phase 2)
Kidney Transplantation (Phase 3)
Menopause (Phase 4)
Metabolic Syndrome (Phase 4)
Myocardial Ischemia (Phase 4)
Obesity (Phase 4)
Osteoporosis (Phase 4)
Oxidative Stress (Phase 4)
Prediabetic State (Phase 3)
Proteinuria (Phase 4)
Renal Insufficiency (Phase 4)
Schizophrenia (Phase 2)
Vascular Diseases (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
